Shervin Tabrizi1, Beow Y Yeap2, Janet C Sherman3, Lisa B Nachtigall4, Mary K Colvin3, Michael Dworkin5, Barbara C Fullerton6, Juliane Daartz5, Trevor J Royce1, Kevin S Oh5, Tracy T Batchelor7, William T Curry8, Jay S Loeffler5, Helen A Shih9. 1. Harvard Radiation Oncology Program, Boston, USA; Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA. 2. Department of Medicine, Massachusetts General Hospital, Boston, USA. 3. Department of Psychiatry, Massachusetts General Hospital, Boston, USA. 4. Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, USA. 5. Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA. 6. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, USA. 7. Department of Neurology, Massachusetts General Hospital, Boston, USA. 8. Department of Neurosurgery, Massachusetts General Hospital, Boston, USA. 9. Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA. Electronic address: hshih@mgh.harvard.edu.
Abstract
BACKGROUND: Patients with low-grade gliomas (LGG) can survive years with their illness. Proton radiotherapy (PRT) can reduce off-target dose and decrease the risk of treatment-related morbidity. We examined long-term morbidity following proton therapy in this updated prospective cohort of patients with LGG. METHODS: Twenty patients with LGG were enrolled prospectively and received PRT to 54 Gy(RBE) in 30 fractions. Comprehensive baseline and longitudinal assessments of toxicity, neurocognitive and neuroendocrine function, quality of life, and survival outcomes were performed up to 5 years following treatment. RESULTS: Six patients died (all of disease) and six had progression of disease. Median follow-up was 6.8 years for the 14 patients alive at time of reporting. Median progression-free survival (PFS) was 4.5 years. Of tumors tested for molecular markers, 71% carried the IDH1-R132H mutation and 29% had 1p/19q co-deletion. There was no overall decline in neurocognitive function; however, a subset of five patients with reported cognitive symptoms after radiation therapy had progressively worse function by neurocognitive testing. Six patients developed neuroendocrine deficiencies, five of which received Dmax ≥20 Gy(RBE) to the hypothalamus-pituitary axis (HPA). Most long-term toxicities developed within 2 years after radiation therapy. CONCLUSIONS: The majority of patients with LGG who received proton therapy retained stable cognitive and neuroendocrine function. The IDH1-R132H mutation was present in the majority, while 1p/19q loss was present in a minority. A subset of patients developed neuroendocrine deficiencies and was more common in those with higher dose to the HPA.
BACKGROUND:Patients with low-grade gliomas (LGG) can survive years with their illness. Proton radiotherapy (PRT) can reduce off-target dose and decrease the risk of treatment-related morbidity. We examined long-term morbidity following proton therapy in this updated prospective cohort of patients with LGG. METHODS: Twenty patients with LGG were enrolled prospectively and received PRT to 54 Gy(RBE) in 30 fractions. Comprehensive baseline and longitudinal assessments of toxicity, neurocognitive and neuroendocrine function, quality of life, and survival outcomes were performed up to 5 years following treatment. RESULTS: Six patientsdied (all of disease) and six had progression of disease. Median follow-up was 6.8 years for the 14 patients alive at time of reporting. Median progression-free survival (PFS) was 4.5 years. Of tumors tested for molecular markers, 71% carried the IDH1-R132H mutation and 29% had 1p/19q co-deletion. There was no overall decline in neurocognitive function; however, a subset of five patients with reported cognitive symptoms after radiation therapy had progressively worse function by neurocognitive testing. Six patients developed neuroendocrine deficiencies, five of which received Dmax ≥20 Gy(RBE) to the hypothalamus-pituitary axis (HPA). Most long-term toxicities developed within 2 years after radiation therapy. CONCLUSIONS: The majority of patients with LGG who received proton therapy retained stable cognitive and neuroendocrine function. The IDH1-R132H mutation was present in the majority, while 1p/19q loss was present in a minority. A subset of patients developed neuroendocrine deficiencies and was more common in those with higher dose to the HPA.
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: Minh-Phuong Huynh-Le; Amanda J Walker; Peter C Burger; George I Jallo; Kenneth J Cohen; Moody D Wharam; Stephanie A Terezakis Journal: Childs Nerv Syst Date: 2016-05-14 Impact factor: 1.475
Authors: Nikolaos Kyriakakis; Julie Lynch; Steve M Orme; Georgina Gerrard; Paul Hatfield; Carmel Loughrey; Susan C Short; Robert D Murray Journal: Clin Endocrinol (Oxf) Date: 2015-11-24 Impact factor: 3.478
Authors: Janet Cohen Sherman; Mary K Colvin; Sarah M Mancuso; Tracy T Batchelor; Kevin S Oh; Jay S Loeffler; Beow Y Yeap; Helen A Shih Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130
Authors: J Jacob; L Feuvret; J-M Simon; M Ribeiro; L Nichelli; C Jenny; D Ricard; D Psimaras; K Hoang-Xuan; P Maingon Journal: Neurol Sci Date: 2022-02-11 Impact factor: 3.307
Authors: Andrew J Bishop; J Andrew Livingston; Matt S Ning; Isaac D Valdez; Cody A Wages; Mary Fran McAleer; Arnold C Paulino; David R Grosshans; Kristina D Woodhouse; Randa Tao; Michael E Roth; G Brandon Gunn; Susan L McGovern Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-04 Impact factor: 8.013
Authors: Sé Maria Frances; Galina Velikova; Martin Klein; Susan C Short; Louise Murray; Judy M Wright; Florien Boele Journal: Neurooncol Pract Date: 2021-11-10
Authors: L Haldbo-Classen; A Amidi; L M Wu; S Lukacova; G Oettingen; Y Lassen-Ramshad; R Zachariae; J F Kallehauge; M Høyer Journal: Clin Transl Radiat Oncol Date: 2021-09-27
Authors: Johannes G Dinkel; Godehard Lahmer; Angelika Mennecke; Stefan W Hock; Tanja Richter-Schmidinger; Rainer Fietkau; Luitpold Distel; Florian Putz; Arnd Dörfler; Manuel A Schmidt Journal: Brain Sci Date: 2022-07-04